Michio Takeda
Overview
Explore the profile of Michio Takeda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Nishi T, et al.
Ther Apher Dial
. 2020 May;
25(1):82-87.
PMID: 32383342
Overhydration is a major cause of technique failure of peritoneal dialysis (PD). Hence, we investigated the impact of ultrafiltration (UF) volume by once-weekly hemodialysis (HD), excess volume beyond their dry...
2.
Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Kawahara T, et al.
Kidney Int Rep
. 2020 Apr;
5(4):468-474.
PMID: 32280842
Introduction: Combination therapy with peritoneal dialysis and hemodialysis (PD+HD) is widely used for PD patients with decreased residual kidney function in Japan; however, hospitalization for this combined dialysis has not...
3.
Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Kawahara T, et al.
Perit Dial Int
. 2020 Feb;
40(5):462-469.
PMID: 32063200
Background: The health-related quality of life (HRQOL) of dialysis patients has not been well examined, especially in combination therapy with peritoneal dialysis and hemodialysis (PD+HD) patients. We compared the HRQOL...
4.
Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Nishi T, et al.
Ther Apher Dial
. 2019 Oct;
24(4):373-379.
PMID: 31626730
Combination therapy with peritoneal dialysis and hemodialysis (PD+HD) is widely used in Japan for PD patients with decreased residual renal function. However, fluid status in PD+HD patients has not been...
5.
Shin H, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, et al.
Nephrology (Carlton)
. 2011 Jan;
16(2):156-62.
PMID: 21272127
Aim: Hyperuricaemia is a significant factor in a variety of diseases, including gout and cardiovascular diseases. The kidney plays a dominant role in maintaining plasma urate levels through the excretion...
6.
Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, et al.
J Pharmacol Sci
. 2010 Jun;
113(3):263-6.
PMID: 20562519
We analyzed the functional properties of five single nucleotide polymorphisms (SNPs) in organic cation transporter OCT3 gene (SLC22A3) resulting in the amino acid changes with a transient expression system. Three...
7.
Babu E, Takeda M, Nishida R, Noshiro-Kofuji R, Yoshida M, Ueda S, et al.
J Pharmacol Sci
. 2010 May;
113(2):192-6.
PMID: 20508390
Aristolochic acids (AAs), contained in Chinese herbal preparations, have been considered to induce nephropathy. In order to elucidate the molecular mechanisms of AA-induced nephrotoxicity, we have elucidated the interaction of...
8.
Tachampa K, Takeda M, Khamdang S, Noshiro-Kofuji R, Tsuda M, Jariyawat S, et al.
J Pharmacol Sci
. 2008 Mar;
106(3):435-43.
PMID: 18319568
Mycotoxins are secondary metabolites of moulds that which exert adverse effects in humans and animals. It is known that direct cellular toxicity is often associated with increased cellular accumulation of...
9.
Anzai N, Jutabha P, Enomoto A, Yokoyama H, Nonoguchi H, Hirata T, et al.
J Pharmacol Exp Ther
. 2005 Aug;
315(2):534-44.
PMID: 16079298
A novel member of the organic anion transporter (OAT) family, Oat5 (Slc22a19), has been reported to transport a naturally occurring mycotoxin, ochratoxin A (OTA). However, neither its endogenous substrate and...
10.
Hasannejad H, Takeda M, Narikawa S, Huang X, Enomoto A, Taki K, et al.
Eur J Pharmacol
. 2004 Sep;
499(1-2):45-51.
PMID: 15363950
Antiarrhythmic drugs have been considered to be transported by the organic cation transport system. The purpose of this study was to elucidate the molecular mechanism underlying the transport of antiarrhythmic...